Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges
Open accessThe DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index; 346 of the 558 sources its claims cite were checked for support.
Abstract
Radiotherapy is a cornerstone of breast cancer treatment, but its efficacy is frequently limited by intrinsic and acquired radioresistance as well as dose-limiting toxicity to surrounding normal tissues. Nanoparticle-mediated radiosensitization has emerged as a promising strategy to enhance the therapeutic index of irradiation by combining physical dose amplification with biological, microenvironmental, and immunological modulation. In this systematic review, we evaluated preclinical evidence on nanoparticle-mediated radiosensitization in breast cancer, with emphasis on nanoplatform design, mechanistic patterns, therapeutic efficacy, and translational relevance. A total of 66 studies published between 2015 and 2026 were included. The identified systems encompassed a broad range of materials, including gold-, silver-, platinum-, bismuth-, gadolinium-, polymer-, lipid-, and hybrid-based nanoplatforms, frequently incorporating targeting ligands, catalytic components, biomimetic coatings, or therapeutic payloads. Enhanced radiation responses were most commonly associated with high-atomic-number (high-Z)-mediated energy deposition, increased reactive oxygen species generation, and enhanced DNA damage persistence. Additional mechanisms, including redox modulation, hypoxia targeting, regulated cell death, and immune activation, reflect the evolution of nanoparticle-assisted radiotherapy from predominantly physical radioenhancement toward multifunctional physicobiological strategies. Triple-negative breast cancer models predominated throughout the literature. Across preclinical models, nanoparticle-assisted irradiation consistently improved clonogenic survival, tumor control, and, in selected studies, survival. However, substantial heterogeneity in study design and limited use of rigorous radiobiological endpoints restricted cross-study comparability. The available preclinical evidence indicates that the most promising nanoparticle-mediated radiosensitization strategies integrate physical dose enhancement with biologically active mechanisms targeting oxidative stress, hypoxia, persistent DNA damage, immune signaling, and tumor microenvironmental resistance. Collectively, these findings suggest that the field is evolving from predominantly physical radioenhancement toward multifunctional, mechanism-driven physicobiological strategies. However, clinical translation remains constrained by methodological heterogeneity and limited radiobiological validation, highlighting the need for standardized preclinical evaluation and clinically feasible nanoplatforms tailored to subtype-specific mechanisms of radioresistance.
Verifying this paper
8 of 9 steps done · this page updates itself — you can leave and come back
- Registry recordVerified
- Full textRead the full text
- Reference list119 references found
- Reference checkChecking each cited work — 119 of 119
- StatisticsRecomputed
- Claims258 claims anchored to a quote
- Cited sourcesChecked
- Self-checkChecked
- VerificationFindings verified
Overview
CoChat Summary
TL;DR
This systematic review synthesizes 66 preclinical studies (2015–2026) on nanoparticle-mediated radiosensitization in breast cancer, finding that enhanced radiation responses are most often linked to high-Z dose amplification, ROS generation, and DNA damage. Multifunctional nanoplatforms show broader therapeutic effects, but clinical translation is constrained by methodological heterogeneity and limited formal radiobiological validation.
Key findings
- Among 66 included studies, triple-negative breast cancer was the predominant model (39/66, 59%), followed by HER2-positive (4/66, 6%), luminal (1/66, 2%), mixed/multiple subtypes (6/66, 9%), and general/unspecified models (16/66, 24%); 44/66 (67%) combined in vitro and in vivo work, 16/66 (24%) were in vitro only, and 6/66 (9%) were in vivo only.
- Mechanistic endpoints were dominated by ROS generation (63/66, 95.5%) and enhanced DNA damage (50/66, 75.8%); regulated cell death was investigated in 32/66 (48.5%), most commonly apoptosis (23/66, 34.8%), while ferroptosis (5/66, 7.6%), immunogenic cell death (3/66, 4.5%), and pyroptosis (2/66, 3.0%) were less frequent; hypoxia modulation and immune activation were reported in 10/66 (15.2%) and 11/66 (16.7%), respectively.
- Formal radiobiological validation was limited: clonogenic survival assays were reported in 26/66 studies (39% or 39.4%), SER/DEF metrics in only 5/66 (8% or 7.6%), survival outcomes in 5/66 (8%), toxicity/safety assessments in 22/66 (33%), and comprehensive radiotherapy protocol reporting in only 8/66 (12%).
- Representative outcomes included CXCR4-targeted gold nanoparticles with a DEF10 of 1.20, Au–Pt bimetallic nanoparticles reducing 4T1 tumor volume from 459.5 ± 76.09 mm³ after irradiation alone to 231.7 ± 63.35 mm³ with combined treatment, HfO2@MnO2–GOx inhibiting primary tumor growth by approximately 67% and distant tumor growth by up to 98.7%, and Au@AgBiS2-PEG leaving approximately 50% of treated animals alive at 60 days versus complete control mortality within 14–43 days.
Methods
- PRISMA-guided systematic review prospectively registered in PROSPERO (CRD420261365298); MEDLINE/PubMed and EMBASE were searched from 1 January 2015 to 2 March 2026 for English-language preclinical original studies on nanoparticle-based radiosensitization in breast cancer with irradiation.
- From 1,905 records, 393 duplicates were removed, 1,512 records were title/abstract screened, 199 full texts were assessed, and 66 studies met inclusion criteria; data were extracted using a predefined framework, and study quality was assessed across six domains.
- Because of heterogeneity in nanoplatforms, models, irradiation protocols, and outcomes, no formal meta-analysis was performed; data were synthesized qualitatively, with radiosensitization distinguished from radioenhancement based on validated endpoints such as clonogenic survival, SER, DEF, or DMF.
Limitations
- The paper states substantial heterogeneity in nanoparticle composition, functionalization, experimental models, radiotherapy protocols, and outcome assessment; radiotherapy reporting was frequently incomplete, especially dose rate, fractionation, beam energy, and treatment timing, and only 8/66 studies (12%) provided comprehensive radiation details.
- The paper states that mechanistic interpretation was often based on associative biomarkers rather than pathway-specific inhibition or rescue experiments, and that formal radiosensitization was inconsistently demonstrated because clonogenic assays and SER/DEF metrics were used in only 26/66 (39%) and 5/66 (8%) studies, respectively.
- The paper also states that TNBC models predominated while HER2-positive and luminal subtypes were underrepresented, that complex integrated nanoplatforms raise concerns about reproducibility, scalability, biodistribution, long-term toxicity, immunogenicity, and regulatory approval, and that publication bias toward positive findings may overestimate benefit; evident from the text, the qualitative design and lack of meta-analysis preclude quantitative cross-platform comparison.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Quantitative overview of the included studies and radiobiological validation endpoints. (A) Distribution of breast cancer molecular subtypes represented in the 66 included studies. (B) Distribution of experimental designs according to the use of in vitro, in vivo, or combined in vitro/in vivo models. (C) Frequency of key radiobiological validation endpoints, including clonogenic survival assays, formal radiosensitization metrics (sensitizer enhancement ratio [SER] or dose enhancement factor [DEF]), and survival assessment. The figure highlights the predominance of triple-negative breast cancer (TNBC) models, the widespread use of combined experimental designs, and the limited use of gold-standard radiobiological validation endpoints across the included literature.](https://figures.cochat.ai/paper-figures/e6bd2dc443b342c8a1b2ee3dc2c898bd/nanoparticle-mediated-radiosensitization-in-breast-cancer-a-systematic-review-of-figure-2.jpg)

Verification
Claims the paper makes
107 Valid · 7 Not valid · 14 Not checked · 130 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Some studies also reported systemic effects, including responses in non-irradiated tumor sites [17,22,36].”
§ Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges > 3. Results > 3.5. Radiosensitization Mechanisms
What the sources say
- Supportedcites [17] Hu H. Zheng S. He C. Zheng Y. Wei Q. Chen S. Wu Z. Xu Y. Zhao B. Yan C. Radiotherapy-sensitized cancer immunotherapy via cGAS-STING immune pathway by activatable nanocascade reaction J. Nanobiotechnol. 2024 22 234 10.1186/s12951-024-02502-8 38724978 PMC11080188 source
The Results and discussion section (“Immune response activation in vivo”; page not provided) reports inhibition of contralateral distant tumors in mice and attributes their regression to a systemic anti-tumor immune response. The Methods describe irradiation applied locally to the tumor region, supporting the description of the distant tumors as non-irradiated sites. (LLM, conf=0.93)
- Supportedcites [22] Chen S.F. Ng P.L. Lai C.W. Wang F.J. Wang Y.C. Chen M.H. Tung F.I. Liu T.Y. Bacterial membrane-modified cerium oxide nanoboosters enhance systemic antitumor effects of radiotherapy in metastatic triple-negative breast cancer J. Nanobiotechnol. 2025 23 105 10.1186/s12951-025-03187-3 39940015 PMC11823237 source
The Results section, “Nanoboosters suppress pre-existing distant tumor proliferation” (page unavailable), reports regression of distant untreated tumors after treatment of the primary tumors with nanoboosters and X-ray irradiation. This supports the claim of a response at non-irradiated tumor sites; the finding was in a mouse model. (LLM, conf=0.93)
- Disputedcites [36] Yu B. Lu X. Feng X. Zhao T. Li J. Lu Y. Ye F. Liu X. Zheng X. Shen Z. Gadolinium Oxide Nanoparticles Reinforce the Fractionated Radiotherapy-Induced Immune Response in Tri-Negative Breast Cancer via cGAS-STING Pathway Int. J. Nanomed. 2023 18 7713 7728 10.2147/ijn.s428044 PMC10729773 38115988 sourceExperimental — accuracy not yet measured
The Results section on in vivo radiosensitization reports improved control of the locally irradiated tumor, but says the treatment did not improve inhibition of lung metastases. Thus, this paper does not report the claimed response at a non-irradiated tumor site; its reported distant-site result points the other way. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Mechanistic conclusions also varied in strength, as increased ROS generation, γ-H2AX expression, or hypoxia-related changes were frequently interpreted as evidence of causal pathway involvement without inhibitor-based or rescue experiments confirming mechanistic specificity [17,21,31,39,45,77].”
§ Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges > 4. Discussion > 4.7. Methodological Limitations of Preclinical Evidence
What the sources say
- Partly supportedcites [17] Hu H. Zheng S. He C. Zheng Y. Wei Q. Chen S. Wu Z. Xu Y. Zhao B. Yan C. Radiotherapy-sensitized cancer immunotherapy via cGAS-STING immune pathway by activatable nanocascade reaction J. Nanobiotechnol. 2024 22 234 10.1186/s12951-024-02502-8 38724978 PMC11080188 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [21] Wang X. Yang Y. Wang P. Li Q. Gao W. Sun Y. Tian G. Zhang G. Xiao J. Oxygen self-supplying nanoradiosensitizer activates cGAS-STING pathway to enhance radioimmunotherapy of triple negative breast cancer J. Control. Release 2024 376 794 805 10.1016/j.jconrel.2024.10.049 39490535 source
- Supportedcites [31] Montazersaheb S. Farahzadi R. Mansouri E. Jafari S. Fathi E. Radiosensitizing effects of silver nanoparticles targeting angiogenesis and matrix metalloproteinase signaling in triple negative breast cancer cell lines Sci. Rep. 2026 16 6820 10.1038/s41598-026-35662-8 41620549 PMC12917104 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Supportedcites [39] Xiao L. Chen B. Wang W. Tian T. Qian H. Li X. Yu Y. Multifunctional Au@AgBiS2 Nanoparticles as High-Efficiency Radiosensitizers to Induce Pyroptosis for Cancer Radioimmunotherapy Adv. Sci. 2023 10 e2302141 10.1002/advs.202302141 PMC10602534 37688340 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [45] Yang Z. Shao B. Wang D. Chen H. Zhao X. Zeng M. Liu Y. Li Q. Bi Z. A TNBC-targeting nano-radiosensitizer reverses radioresistance by synergizing GSH scavenging with dual inhibition of Trop2 and lncRNA MNX1-AS1 Biomaterials 2026 327 123787 10.1016/j.biomaterials.2025.123787 41130126 source
- Disputedcites [77] Aishajiang R. Liu Z. Liang Y. Du P. Wei Y. Zhuo X. Liu S. Lei P. Wang T. Yu D. Concurrent Amplification of Ferroptosis and Immune System Activation Via Nanomedicine-Mediated Radiosensitization for Triple-Negative Breast Cancer Therapy Adv. Sci. 2025 12 e2407833 PMC11831504 39721034 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 2 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Biomimetic strategies, including cell membrane-coated nanoparticles, were reported to enhance circulation time and immune evasion [34,44,50,56].”
§ Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges > 3. Results > 3.3. Characteristics of Nanoplatforms, Experimental Models, and Radiotherapy Protocols
What the sources say
- Not checked — no full text of the sourcecites [34] Deng J. Xu S. Hu W. Xun X. Zheng L. Su M. Tumor targeted, stealthy and degradable bismuth nanoparticles for enhanced X-ray radiation therapy of breast cancer Biomaterials 2018 154 24 33 10.1016/j.biomaterials.2017.10.048 29120816 source
- Supportedcites [44] Chen S. Wang C. Meng Y. Li P. Pan Y. He M. Ni X. Nanofabrications of Erythrocyte Membrane-Coated Telmisartan Delivery System Effective for Radiosensitivity of Tumor Cells in Mice Model Int. J. Nanomed. 2024 19 1487 1508 10.2147/ijn.s441418 PMC10878400 38380147 source
The Introduction states that biomimetic erythrocyte-membrane coating can help a drug-delivery system escape macrophage recognition and clearance, and that ECM-coated systems have long circulation in vivo. These statements support the attributed claim about immune evasion and circulation time. (LLM, conf=0.93)
- Partly supportedcites [50] Zhang Y. Liu Y. Zheng D. Novel Pt@BSA nanoparticles improve radiotherapeutic outcomes in breast cancer RSC Med. Chem. 2026 17 1187 1199 10.1039/d5md00792e 41551020 PMC12809708 sourceExperimental — accuracy not yet measured
The Abstract identifies Pt@BSA-RM as a biomimetic, red blood cell membrane-coated nanoparticle. The Introduction (page unavailable) attributes a long circulation half-life to its BSA shell, not to the membrane coating; our copy does not report immune evasion by the nanoparticles. Thus the paper supports the example and part of the circulation claim, but not the claimed immune-evasion benefit. (LLM, conf=0.84)
- Partly supportedcites [56] Wang D. Lin S. Li T. Yang X. Zhong X. Chen Q. Jiang G. Li C. Cancer cell membrane-coated siRNA-Decorated Au/MnO2 nanosensitizers for synergistically enhanced radio-immunotherapy of breast cancer Mater. Today Bio 2024 29 101275 10.1016/j.mtbio.2024.101275 39403312 PMC11471673 sourceExperimental — accuracy not yet measured
The Results and discussion section (‘In vivo homologous targeting and anti-tumor efficiency’; page unavailable) reports a 3.79-hour blood half-life for the cell membrane-coated nanosensitizer and calls its circulation characteristics favorable. It does not show that membrane coating increased circulation time relative to an uncoated comparator or that the nanoparticles evaded immune clearance. Its discussion of immune evasion concerns tumor-cell PD-L1, not nanoparticle immune evasion. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Receptor-specific targeting approaches, including HER2-, CXCR4-, and folate-directed systems, were described in association with increased cellular uptake [20,24,29,51,54,55].”
§ Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges > 3. Results > 3.3. Characteristics of Nanoplatforms, Experimental Models, and Radiotherapy Protocols
What the sources say
- Supportedcites [20] Bhattarai S. Mackeyev Y. Venkatesulu B.P. Krishnan S. Singh P.K. CXC chemokine receptor 4 (CXCR4) targeted gold nanoparticles potently enhance radiotherapy outcomes in breast cancer Nanoscale 2021 13 19056 19065 10.1039/d1nr05385j 34757363 PMC9124374 source
The Results section (‘Uptake of cGNPs by MDA-MB-231 breast cancer cells’) reports greater cellular uptake of CXCR4-targeted gold nanoparticles than of untargeted particles. The Discussion likewise associates CXCR4 targeting with increased uptake and internalization. This source supports the CXCR4 example in the multiply cited sentence; the HER2 and folate examples are not attributed specifically to it. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [24] Samani R.K. Tavakoli M.B. Maghsoudinia F. Motaghi H. Hejazi S.H. Mehrgardi M.A. Trastuzumab and folic acid functionalized gold nanoclusters as a dual-targeted radiosensitizer for megavoltage radiation therapy of human breast cancer Eur. J. Pharm. Sci. 2020 153 105487 10.1016/j.ejps.2020.105487 32707173 source
- Supportedcites [29] Babaye Abdollahi B. Ghorbani M. Hamishehkar H. Malekzadeh R. Farajollahi A. Synthesis and characterization of actively HER-2 Targeted Fe3O4@Au nanoparticles for molecular radiosensitization of breast cancer Bioimpacts 2023 13 17 29 36816996 PMC9923814 source
The Cellular uptake results report greater uptake of trastuzumab-coated nanoparticles than untargeted particles, and the Discussion attributes this to HER-2 overexpression. This supports the HER2-directed example for which this paper is cited in the multi-citation sentence. (LLM, conf=0.92)
- Supportedcites [51] Yamaguchi H. Hayama K. Sasagawa I. Okada Y. Kawase T. Tsubokawa N. Tsuchimochi M. HER2-targeted multifunctional silica nanoparticles specifically enhance the radiosensitivity of HER2-overexpressing breast cancer cells Int. J. Mol. Sci. 2018 19 908 10.3390/ijms19030908 29562708 PMC5877769 source
The Results (§2.1; page unavailable) report that anti-HER2 PCSN probes were internalized by HER2-overexpressing SK-BR3 cells and describe stronger cell-surface fluorescence than in a HER2-negative control. This supports the HER2-targeting and cellular-uptake portion attributable to this paper; the other citations in the sentence address the other receptor-directed systems. (LLM, conf=0.88)
- Partly supportedcites [54] Nosrati H. Ghaffarlou M. Salehiabar M. Mousazadeh N. Abhari F. Barsbay M. Ertas Y.N. Rashidzadeh H. Mohammadi A. Nasehi L. Magnetite and bismuth sulfide Janus heterostructures as radiosensitizers for in vivo enhanced radiotherapy in breast cancer Biomater. Adv. 2022 140 213090 10.1016/j.bioadv.2022.213090 36027669 sourceExperimental — accuracy not yet measured
Section 3.3.4 (page unavailable) reports that folic-acid conjugation enhanced nanoparticle internalization compared with non-targeted particles. The cited paper supports the folate-directed part of the sentence, but the passages do not describe HER2- or CXCR4-directed uptake. (LLM, conf=0.88)
- Partly supportedcites [55] Ghaffarlou M. Mohammadi A. Mousazadeh N. Salehiabar M. Kalantari Y. Charmi J. Barsbay M. Ertas Y.N. Danafar H. Rezaeejam H. Facile preparation of silver based radiosensitizers via biomineralization method for enhanced in vivo breast cancer radiotherapy Sci. Rep. 2023 13 15131 10.1038/s41598-023-40763-9 37704633 PMC10499791 sourceExperimental — accuracy not yet measured
The Results section (‘Cellular uptake and internalization efficacy’; page not provided) reports greater uptake of folic-acid-conjugated nanoparticles than unconjugated nanoparticles by 4T1 breast cancer cells and links this to folate receptors. The cited paper does not describe HER2- or CXCR4-directed uptake, so it supports only the folate-directed part of the sentence. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Increased ROS production and DNA damage following irradiation were commonly reported in association with these systems [15,20,27,30,33], as summarized in Table 2.”
§ Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges > 3. Results > 3.4. Nanoplatform Design and Functionalization Strategies
What the sources say
- Supportedcites [15] Sun H. Cai H. Xu C. Zhai H. Lux F. Xie Y. Feng L. Du L. Liu Y. Sun X. AGuIX nanoparticles enhance ionizing radiation-induced ferroptosis on tumor cells by targeting the NRF2-GPX4 signaling pathway J. Nanobiotechnol. 2022 20 449 10.1186/s12951-022-01654-9 36242003 PMC9569109 source
The Results section reports that irradiated breast cancer cells treated with AGuIX nanoparticles produced more ROS and showed more DNA fragmentation and γH2AX foci than cells receiving irradiation alone. This paper supports the cited sentence as one reported example; page numbers are not available in the supplied copy. (LLM, conf=0.92)
- Supportedcites [20] Bhattarai S. Mackeyev Y. Venkatesulu B.P. Krishnan S. Singh P.K. CXC chemokine receptor 4 (CXCR4) targeted gold nanoparticles potently enhance radiotherapy outcomes in breast cancer Nanoscale 2021 13 19056 19065 10.1039/d1nr05385j 34757363 PMC9124374 source
The Results sections on reactive oxygen species and DNA double-strand breaks report that CXCR4-targeted gold nanoparticles increased both outcomes after irradiation of MDA-MB-231 breast cancer cells, compared with radiation alone. This paper supports the cited sentence as an example of those effects in a high-Z gold nanoparticle system. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [27] Cui L. Her S. Dunne M. Borst G.R. De Souza R. Bristow R.G. Jaffray D.A. Allen C. Significant Radiation Enhancement Effects by Gold Nanoparticles in Combination with Cisplatin in Triple Negative Breast Cancer Cells and Tumor Xenografts Radiat. Res. 2017 187 147 160 10.1667/rr14578.1 28085639 source
- Partly supportedcites [30] Swanner J. Mims J. Carroll D.L. Akman S.A. Furdui C.M. Torti S.V. Singh R.N. Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells Int. J. Nanomed. 2015 10 3937 3953 10.2147/ijn.s80349 PMC4501353 26185437 sourceExperimental — accuracy not yet measured
The Results section reports increased DNA-damage marker γH2AX after irradiation in silver-nanoparticle-treated breast cells compared with radiation alone. The Discussion says silver nanoparticles increase intracellular ROS, but does not establish increased ROS production following irradiation; it describes ROS findings from nanoparticle exposure without that condition. No page numbers are available in our copy. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [33] Rashidzadeh H. Seidi F. Ghaffarlou M. Salehiabar M. Charmi J. Yaray K. Nosrati H. Ertas Y.N. Preparation of alginate coated Pt nanoparticle for radiosensitization of breast cancer tumor Int. J. Biol. Macromol. 2023 233 123273 10.1016/j.ijbiomac.2023.123273 36646349 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
177 more claims · 67 with their cited sources checked
Create a free account to see all 258 claims and every source verdict.
- It may state two separate claims as one. 69
- Probably not a substantial claim. 11
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges > 4. Discussion > 4.8. Barriers to Clinical Translation
“Although NBTXR3 is currently being evaluated in a phase I dose-escalation/dose-expansion study that includes metastatic triple-negative breast cancer among the expansion cohorts, dedicated breast cancer clinical data remain limited [118,119].”
§ Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges > References
“118. A Phase II Study of High Dose Radiotherapy in Combination with Pembrolizumab Plus Chemotherapy in Patients with PD-L1 Positive Metastatic Triple Negative Breast Cancer (NCT06492759) ClinicalTrials.gov Available online: https://clinicaltrials.gov (accessed on 25 June 2026)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges > 4. Discussion > 4.2. Functional Categories of Nanoparticle-Mediated Radiosensitization
“The most advanced category comprises multifunctional nanoplatforms integrating multiple complementary radiosensitization strategies within a single system [17,21,23,26,39,40,45,52,53].”
§ Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges > 3. Results > 3.3. Characteristics of Nanoplatforms, Experimental Models, and Radiotherapy Protocols
“[15,16,17,19,20,21,22,24,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84]”
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873 · cited 5×
“…local radiation absorption, secondary electron generation, and ROS production, they do not directly address major biological determinants of radioresistance, including tumor hypoxia, antioxidant defenses, DNA repair capacity, immune suppression, and heterogeneous nanoparticle delivery [4,12,85,93].”
InfluentialMaeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376 · cited 3×
“Nanoparticles can be engineered with precise control over size, shape, composition, and surface functionalization, enabling tailored interactions with biological systems and selective accumulation in tumor tissues [11,12].”
Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements
Her, S., Jaffray, D. A., & Allen, C. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.012 · Cited by 865 · cited 3×
“…radiosensitization is the use of high-atomic-number (high-Z) materials, such as gold, hafnium, bismuth, and gadolinium, which exhibit increased photoelectric absorption and generate secondary electrons under irradiation, thereby amplifying local radiation dose deposition [9,13].”
Opportunities and challenges of radiotherapy for treating cancer
Schaue, D., & McBride, W. H. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.120 · Cited by 784 · cited 2×
“Hypoxia is one of the most important determinants of radiotherapy response because reduced oxygen availability limits stabilization of radiation-induced DNA damage and decreases sensitivity to ionizing radiation [6].”
Pathogenesis of Triple-Negative Breast Cancer
Derakhshan, F., & Reis-Filho, J. S. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042420-093238 · Cited by 714 · cited 4×
“These challenges are particularly pronounced in aggressive subtypes such as triple-negative breast cancer (TNBC), which is characterized by high genomic instability, lack of actionable receptors, and poor clinical outcomes [8].”
InfluentialGold Nanoparticles as Radiosensitizers in Cancer Radiotherapy
Chen, Y., Yang, J., Fu, S., & Wu, J. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s272902 · Cited by 319 · cited 9×
“Nanotechnology has emerged as a promising strategy for enhancing radiation response because nanoparticles can be engineered to promote both physical dose amplification and biological modulation, thereby increasing the potential for radiosensitization [9,10].”
InfluentialBonvalot, S., Le Pechoux, C., De Baere, T., Kantor, G., Buy, X., Stoeckle, E., Terrier, P., Sargos, P., Coindre, J. M., Lassau, N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1297 · Cited by 243 · cited 2×
“Hafnium oxide nanoparticles (NBTXR3/Hensify) represent the most advanced example, demonstrating clinical efficacy in combination with radiotherapy and obtaining regulatory approval for locally advanced soft tissue sarcoma, with ongoing evaluation in additional tumor types [112–115].”
Deng, J., Xu, S., Hu, W., Xun, X., Zheng, L., & Su, M. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.048 · Cited by 234 · cited 8×
“[15,20,27,28,30,33,34,36,50,63].”
InfluentialEngineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy
Gao, J., Wang, W.-Q., Pei, Q., Lord, M. S., & Yu, H.-J. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0400-z · Cited by 203 · cited 1×
“Although definitive abscopal responses remain uncommon in breast cancer models, increasing evidence for ICD induction, cGAS–STING activation, and immune-cell infiltration suggests that immune modulation represents an important component of nanoparticle-mediated radiosensitiza-https tion [92].”
Verry, C., Dufort, S., Villa, J., Gavard, M., Iriart, C., Grand, S., Charles, J., Chovelon, B., Cracowski, J.-L., Quesada, J.-L., et al. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.04.021 · Cited by 173
Exosome for mRNA delivery: Strategies and therapeutic applications
Iqbal, Z., Rehman, K., Mahmood, A., Shabbir, M., Liang, Y., Duan, L., & Zeng, H. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02634-x · Cited by 144
Singh, R., Swanner, J., Mims, J., Akman, S., Furdui, C., Torti, S., & Carroll, D. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s80349 · Cited by 130
Hybrid Manganese Dioxide Nanoparticles Potentiate Radiation Therapy by Modulating Tumor Hypoxia
Abbasi, A. Z., Gordijo, C. R., Amini, M. A., Maeda, A., Rauth, A. M., DaCosta, R. S., & Wu, X. Y. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3475 · Cited by 121 · cited 10×
“Such systems frequently incorporated catalytic and microenvironment-responsive components designed to address tumor hypoxia, redox imbalance, and metabolic vulnerabilities within the tumor microenvironment [17,19,21,43,47,53].”
InfluentialRadiosensitizing effect of curcumin-loaded lipid nanoparticles in breast cancer cells
Minafra, L., Porcino, N., Bravatà, V., Gaglio, D., Bonanomi, M., Amore, E., Cammarata, F. P., Russo, G., Militello, C., Savoca, G., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47553-2 · Cited by 108 · cited 3×
“Therapeutic payload delivery was reported across multiple studies, including chemotherapeutic agents, epigenetic modulators, and nucleic acid-based therapeutics [16,27,42,45,52].”
Sun, H., Cai, H., Xu, C., Zhai, H., Lux, F., Xie, Y., Feng, L., Du, L., Liu, Y., Sun, X., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01654-9 · Cited by 86 · cited 10×
“[15,20,27,28,30,33,34,36,50,63].”
InfluentialAu-Pt Nanoparticle Formulation as a Radiosensitizer for Radiotherapy with Dual Effects
Yang, S., Han, G., Chen, Q., Yu, L., Wang, P., Zhang, Q., Dong, J., Zhang, W., & Huang, J. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s287523 · Cited by 81 · cited 3×
“Au –Pt bimetallic nanoparticles reduced 4T1 tumor volume from 459.5 ± 76.09 mm 3 after irradiation alone to 231.7 ± 63.35 mm 3 following combined treatment without evident systemic toxicity [84].”
InfluentialThivat, E., Casile, M., Moreau, J., Molnar, I., Dufort, S., Seddik, K., Le Duc, G., De Beaumont, O., Loeffler, M., Durando, X., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10829-y · Cited by 76 · cited 1×
“Similarly, gadolinium-based nanoparticles such as AGuIX have progressed into clinical trials, particularly in brain metastases and other indications, demonstrating feasibility, imaging capability, and preliminary therapeutic benefit [114–117].”
Enhanced In Vivo Radiotherapy of Breast Cancer Using Gadolinium Oxide and Gold Hybrid Nanoparticles
Nosrati, H., Salehiabar, M., Charmi, J., Yaray, K., Ghaffarlou, M., Balcioglu, E., & Ertas, Y. N. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00965 · Cited by 73 · cited 3×
“…in nanoparticle composition, particle size, surface functionalization, therapeutic payloads, irradiation protocols, experimental models, and outcome assessment methods [15,20,24,33,37,45,52,68,76,81] substantially complicate direct cross-study comparison and limit quantitative synthesis.”
Hu, B., Xiao, X., Chen, P., Qian, J., Yuan, G., Ye, Y., Zeng, L., Zhong, S., Wang, X., Qin, X., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121811 · Cited by 73 · cited 1×
“More recently, RuCu bimetallic nanozymes demonstrated dual peroxidase-like and catalase-like activities, simultaneously enhancing ROS production and alleviating tumor hypoxia under irradiation in MDA-MB-231 breast cancer models [101].”
Ghahremani, F., Kefayat, A., Shahbazi-Gahrouei, D., Motaghi, H., Mehrgardi, M. A., & Haghjooy-Javanmard, S. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0180 · Cited by 70 · cited 2×
“Early studies predominantly investigated relatively simple high-Z nanostructures designed primarily to maximize physical dose enhancement through radiation energy deposition [30,64,65].”
Xu, Q., Zhang, M., Huang, Q., Gao, S., Chu, S., Li, Q., Chen, W., Zhang, X., Zhang, T., Tang, B. Z., et al. (2025) · Advanced Materials · doi:10.1002/adma.202502898 · Cited by 69
Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges
Ubanako, P., Mirza, S., Ruff, P., & Penny, C. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1447953 · Cited by 68 · cited 1×
“In particular, exosome-based and exosome-mimicking systems have attracted increasing interest because of their intrinsic biocompatibility, tumor-homing potential, and ability to facilitate intracellular transport of functional cargo [106–108].”
Xiao, L., Chen, B., Wang, W., Tian, T., Qian, H., Li, X., & Yu, Y. (2023) · Advanced Science · doi:10.1002/advs.202302141 · Cited by 64 · cited 9×
“Combined treatment was associated with greater tumor growth delay or regression compared to radiotherapy alone [17,20,39,40,43,50,63,80].”
InfluentialRadiosensitization of breast cancer cells using AS1411 aptamer-conjugated gold nanoparticles
Mehrnia, S. S., Hashemi, B., Mowla, S. J., Nikkhah, M., & Arbabi, A. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01751-3 · Cited by 60 · cited 1×
“Clonogenic survival assays demonstrated reduced survival fractions in nanoparticle-treated cells compared to radiotherapy alone [20,30,33,79].”
Nosrati, H., Ghaffarlou, M., Salehiabar, M., Mousazadeh, N., Abhari, F., Barsbay, M., Ertas, Y. N., Rashidzadeh, H., Mohammadi, A., Nasehi, L., et al. (2022) · Biomaterials Advances · doi:10.1016/j.bioadv.2022.213090 · Cited by 60 · cited 4×
“From an experimental standpoint, most studies employed both in vitro and in vivo approaches [17,20,27,39,54], whereas a smaller subset relied exclusively on a single model type [30,57,58].”
InfluentialCui, L., Her, S., Dunne, M., Borst, G. R., De Souza, R., Bristow, R. G., Jaffray, D. A., & Allen, C. (2017) · Radiation Research · doi:10.1667/rr14578.1 · Cited by 58 · cited 10×
“[15,20,27,28,30,33,34,36,50,63].”
InfluentialChoi, B. J., Jung, K. O., Graves, E. E., & Pratx, G. (2018) · Nanotechnology · doi:10.1088/1361-6528/aae272 · Cited by 57
Kefayat, A., Ghahremani, F., Motaghi, H., & Mehrgardi, M. A. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.01.037 · Cited by 54 · cited 1×
“Early studies predominantly investigated relatively simple high-Z nanostructures designed primarily to maximize physical dose enhancement through radiation energy deposition [30,64,65].”
Application of High-Z Nanoparticles to Enhance Current Radiotherapy Treatment
Jackson, N., Cecchi, D., Beckham, W., & Chithrani, D. B. (2024) · Molecules · doi:10.3390/molecules29112438 · Cited by 52 · cited 10×
“…pharmacokinetics, long-term toxicity, immunogenicity, manufacturing scalability, and regulatory reproducibility were infrequently evaluated [10,11,13,16,93–100 , 102 Taken together, these limitations highlight the need for greater methodological standardization in preclinical…”
InfluentialBilynsky, C., Millot, N., & Papa, A. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10256 · Cited by 52 · cited 1×
“Similarly, gadolinium-based nanoparticles such as AGuIX have progressed into clinical trials, particularly in brain metastases and other indications, demonstrating feasibility, imaging capability, and preliminary therapeutic benefit [114–117].”
Zhao, N., Yang, Z., Li, B., Meng, J., Shi, Z., Li, P., & Fu, S. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s104034 · Cited by 51 · cited 3×
“…between 2015 and early 2026, exhibited substantial heterogeneity in nanomaterial composition, functionalization strategies, experimental models, and radiotherapy protocols [15–17,19 – Zhao (2016) Notes: Mechanistic and outcome classifications summarize the findings reported in the original studies.”
Colak, B., & Ertas, Y. N. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c17024 · Cited by 50 · cited 1×
“Safety assessments were reported in a proportion of studies, with limited systemic toxicity observed based on body weight, organ histology, and hematological parameters [34,40,48,83].”
Liu, T.-I., Lu, T.-Y., Yang, Y.-C., Chang, S.-H., Chen, H.-H., Lu, I.-L., Sabu, A., & Chiu, H.-C. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120229 · Cited by 50 · cited 6×
“Such systems frequently incorporated catalytic and microenvironment-responsive components designed to address tumor hypoxia, redox imbalance, and metabolic vulnerabilities within the tumor microenvironment [17,19,21,43,47,53].”
InfluentialHullo, M., Grall, R., Perrot, Y., Mathé, C., Ménard, V., Yang, X., Lacombe, S., Porcel, E., Villagrasa, C., Chevillard, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094436 · Cited by 48 · cited 1×
“…frequently associated with enhanced therapeutic activity compared with radiotherapy alone, including reduced cell viability, decreased clonogenic survival, increased apoptosis, enhanced DNA damage, delayed tumor growth, and, in selected studies, improved survival outcomes [14,23,26,87,96,104,105].”
Research progress on nano-sensitizers for enhancing the effects of radiotherapy
Zhang, Y., Han, X., Liu, Y., Wang, S., Han, X., & Cheng, C. (2022) · Materials Advances · doi:10.1039/d2ma00094f · Cited by 44 · cited 8×
“…local radiation absorption, secondary electron generation, and ROS production, they do not directly address major biological determinants of radioresistance, including tumor hypoxia, antioxidant defenses, DNA repair capacity, immune suppression, and heterogeneous nanoparticle delivery [4,12,85,93].”
InfluentialPreparation of alginate coated Pt nanoparticle for radiosensitization of breast cancer tumor
Rashidzadeh, H., Seidi, F., Ghaffarlou, M., Salehiabar, M., Charmi, J., Yaray, K., Nosrati, H., & Ertas, Y. N. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123273 · Cited by 43 · cited 10×
“[15,20,27,28,30,33,34,36,50,63].”
InfluentialHu, H., Zheng, S., He, C., Zheng, Y., Wei, Q., Chen, S., Wu, Z., Xu, Y., Zhao, B., & Yan, C. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02502-8 · Cited by 43 · cited 9×
“Many nanoplatforms incorporated targeting ligands, therapeutic payloads, and microenvironment-responsive components [16,17,26,27,45,49,51–53].”
InfluentialSamani, R. K., Tavakoli, M. B., Maghsoudinia, F., Motaghi, H., Hejazi, S. H., & Mehrgardi, M. A. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105487 · Cited by 40 · cited 10×
“In contrast, triple-negative breast cancer (TNBC) lacks HER2 expression and therefore requires alternative receptor-targeting or microenvironment-targeting approaches for selective nanoparticle delivery [20,24].”
InfluentialDhiman, R., Bazad, N., Mukherjee, R., Himanshu, Gunjan, Leal, E., Ahmad, S., Kaur, K., Raj, V. S., Chang, C.-M., et al. (2024) · Discover Nano · doi:10.1186/s11671-024-04086-6 · Cited by 40 · cited 2×
“Early studies predominantly focused on high-atomic-number (high-Z) materials, including gold, silver, gadolinium, and hafnium-based nanoparticles, with the primary objective of maximizing radiation energy deposition and secondary electron generation [9,85,95,96].”
Advances in Radiotherapy for Breast Cancer
Upadhyay, R., & Bazan, J. G. (2023) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2023.03.002 · Cited by 39 · cited 4×
“…radiosensitization represents a particularly attractive therapeutic strategy because radiotherapy plays a central role in disease management, yet treatment response varies substantially among molecular subtypes and is influenced by multiple biological determinants of radioresistance [3].”
InfluentialArab-Bafrani, Z., Zabihi, E., Jafari, S. M., Khoshbin-Khoshnazar, A., Mousavi, E., Khalili, M., & Babaei, A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120828 · Cited by 39
Nosrati, H., Baghdadchi, Y., Abbasi, R., Barsbay, M., Ghaffarlou, M., Abhari, F., Mohammadi, A., Kavetskyy, T., Bochani, S., Rezaeejam, H., et al. (2021) · Journal of Materials Chemistry B · doi:10.1039/d0tb02561e · Cited by 37 · cited 3×
“Combined treatment was associated with greater tumor growth delay or regression compared to radiotherapy alone [17,20,39,40,43,50,63,80].”
Nanoscale Mixed-Ligand Metal–Organic Framework for X-ray Stimulated Cancer Therapy
Zhen, W., Xu, Z., Mao, Y., McCleary, C., Jiang, X., Weichselbaum, R. R., & Lin, W. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c12140 · Cited by 37
Talik Sisin, N. N., Abdul Razak, K., Zainal Abidin, S., Che Mat, N. F., Abdullah, R., Ab Rashid, R., Khairil Anuar, M. A., & Rahman, W. N. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s269214 · Cited by 36
Review of clinical applications of radiation-enhancing nanoparticles
Scher, N., Bonvalot, S., Le Tourneau, C., Chajon, E., Verry, C., Thariat, J., & Calugaru, V. (2020) · Biotechnology Reports · doi:10.1016/j.btre.2020.e00548 · Cited by 35 · cited 2×
“Hafnium oxide nanoparticles (NBTXR3/Hensify) represent the most advanced example, demonstrating clinical efficacy in combination with radiotherapy and obtaining regulatory approval for locally advanced soft tissue sarcoma, with ongoing evaluation in additional tumor types [112–115].”
Samad, M. A., Ahmad, I., Zughaibi, T. A., Suhail, M., Zaidi, S. K., Al-Abbasi, F. A., & Tabrez, S. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100268 · Cited by 35 · cited 5×
“Although these combinatorial systems often demonstrate enhanced efficacy experimentally, their clinical development is challenged by issues related to reproducibility, manufacturing consistency, regulatory approval, scalability, and long-term safety [25,96,97].”
InfluentialTudda, A., Donzelli, E., Nicolini, G., Semperboni, S., Bossi, M., Cavaletti, G., Castriconi, R., Mangili, P., Vecchio, A. D., Sarno, A., et al. (2022) · Medical Physics · doi:10.1002/mp.15348 · Cited by 34 · cited 3×
“…demonstrating dose enhancement factors of approximately 1.3 under kilovoltage irradiation in breast cancer models, while more advanced multifunctional systems achieve sensitizer enhancement ratios exceeding 1.5 through combined oxidative and intracellular damage pathways [14,23,87,89].”
InfluentialJian, C., Wu, T., Wang, L., Gao, C., Fu, Z., Zhang, Q., & Shi, C. (2024) · Small · doi:10.1002/smll.202309279 · Cited by 33 · cited 1×
“Immune-related effects, including cGAS–STING activation and increased immune cell infiltration, have also been described following nanoparticle-assisted irradiation [18,23,26,91].”
Cline, B. L., Jiang, W., Lee, C., Cao, Z., Yang, X., Zhan, S., Chong, H., Zhang, T., Han, Z., Wu, X., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c01435 · Cited by 32 · cited 2×
“X-ray X-ray irradiation was the most frequently reported modality [17,20,27,34,54], whereas megavoltage radiation and radionuclide-based approaches were less commonly used [20,24,61,62].”
Radiotherapy and radiosensitization in breast cancer: Molecular targets and clinical applications
Bhat, V., Pellizzari, S., Allan, A. L., Wong, E., Lock, M., Brackstone, M., Lohmann, A. E., Cescon, D. W., & Parsyan, A. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103566 · Cited by 31 · cited 5×
“Moreover, breast cancer exhibits marked biological heterogeneity across molecular subtypes, further increasing the complexity of patient selection and treatment optimization [2,7,8].”
InfluentialAishajiang, R., Liu, Z., Liang, Y., Du, P., Wei, Y., Zhuo, X., Liu, S., Lei, P., Wang, T., & Yu, D. (2025) · Advanced Science · doi:10.1002/advs.202407833 · Cited by 31 · cited 8×
“Ferroptosis was reported in several studies, particularly in association with redox modulation and glutathione depletion [15,17,68,77,78], while additional pathways such as pyroptosis were also described [16,39].”
InfluentialBromma, K., Rieck, K., Kulkarni, J. A., O’Sullivan, C., Sung, W., Cullis, P. R., Schuemann, J., & Chithrani, D. B. (2019) · Cancer Nanotechnology · doi:10.1186/s12645-019-0046-z · Cited by 31
A tumor cell exosome-mimicking multifunctional nanozyme for targeted breast cancer radiotherapy
Chen, G., Jiang, D., Ding, S., Huang, C., Zhu, D., & Jiang, H. (2023) · Nanoscale · doi:10.1039/d3nr03065b · Cited by 31 · cited 1×
“…siRNA delivery, these findings suggest that biologically inspired delivery systems may further enhance the therapeutic potential of nucleic acid-based radiosensitization strategies by improving intracellular delivery, protecting RNA cargo from degradation, and reducing off-target effects [109–111].”
Yamaguchi, H., Hayama, K., Sasagawa, I., Okada, Y., Kawase, T., Tsubokawa, N., & Tsuchimochi, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030908 · Cited by 30 · cited 4×
“Many nanoplatforms incorporated targeting ligands, therapeutic payloads, and microenvironment-responsive components [16,17,26,27,45,49,51–53].”
InfluentialShiridokht, F., Dadashi, H., Vandghanooni, S., Eskandani, M., & Farajollahi, A. (2025) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2024.114220 · Cited by 30 · cited 2×
“Additional findings included decreased cell viability and increased apoptosis following combined nanoparticle and radiotherapy treatment [20,27,33,50,59,72].”
Babaye Abdollahi, B., Ghorbani, M., Hamishehkar, H., Malekzadeh, R., & Farajollahi, A. (2023) · BioImpacts · doi:10.34172/bi.2022.23682 · Cited by 29
Askar, M. A., Thabet, N. M., El-Sayyad, G. S., El-Batal, A. I., Elkodous, M. A., Kawamura, G., Matsuda, A., Elshawi, O. E., Helal, H., & Abdel-Rafei, M. K. (2021) · Cancers · doi:10.3390/cancers13215571 · Cited by 28
Detappe, A., Mathieu, C., Jin, C., Agius, M. P., Diringer, M.-C., Tran, V.-L., Pivot, X., Lux, F., Tillement, O., Kufe, D., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.06.069 · Cited by 27 · cited 1×
“…was placed on functional modifications, including surface coatings, targeting ligands, biomimetic components, and therapeutic payloads, giving rise to multifunctional nanoplatforms capable of improving cellular uptake and integrating biological mechanisms of radiosensitization [24,27,29,55,66].”
Askar, M. A., Thabet, N. M., El-sayyad, G. S., El-Batal, A. I., kodous, M. A. E., Kawamura, G., Matsuda, A., Shawi, O. E. E., Helal, H., & Abdel-Rafei, M. K. (2021) · doi:10.21203/rs.3.rs-910507/v1 · Cited by 27
Wang, X., Yang, Y., Wang, P., Li, Q., Gao, W., Sun, Y., Tian, G., Zhang, G., & Xiao, J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.049 · Cited by 26 · cited 10×
“Such systems frequently incorporated catalytic and microenvironment-responsive components designed to address tumor hypoxia, redox imbalance, and metabolic vulnerabilities within the tumor microenvironment [17,19,21,43,47,53].”
InfluentialZhang, F., Feng, L., Jia, C., Wu, Y., Liu, J., Shuai, X., & Cao, Z. (2023) · Nano Today · doi:10.1016/j.nantod.2022.101708 · Cited by 26
Wu, Z., Stangl, S., Hernandez-Schnelzer, A., Wang, F., Hasanzadeh Kafshgari, M., Bashiri Dezfouli, A., & Multhoff, G. (2023) · Cancers · doi:10.3390/cancers15041167 · Cited by 24
Asadi, N., Gharbavi, M., Rezaeejam, H., Farajollahi, A., & Johari, B. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124285 · Cited by 23 · cited 1×
“Additional findings included decreased cell viability and increased apoptosis following combined nanoparticle and radiotherapy treatment [20,27,33,50,59,72].”
Yu, B., Lu, X., Feng, X., Zhao, T., Li, J., Lu, Y., Ye, F., Liu, X., Zheng, X., Shen, Z., et al. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s428044 · Cited by 23 · cited 7×
“[15,20,27,28,30,33,34,36,50,63].”
InfluentialLiu, R., Wang, R., Zhao, M., Liu, Y., Zhu, X., Wu, X., Du, S., Gu, Z., & Du, J. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101997 · Cited by 23 · cited 5×
“Many nanoplatforms incorporated targeting ligands, therapeutic payloads, and microenvironment-responsive components [16,17,26,27,45,49,51–53].”
InfluentialEnhancing Proton Therapy Efficacy Through Nanoparticle-Mediated Radiosensitization
Ma, J., Shen, H., & Mi, Z. (2024) · Cells · doi:10.3390/cells13221841 · Cited by 23 · cited 1×
“High-Z nanoparticles enhance ROS generation by increasing local energy deposition and secondary electron emission, thereby amplifying free radical formation and oxidative stress following irradiation [9,10,86,88,102,103].”
Bhattarai, S., Mackeyev, Y., Venkatesulu, B. P., Krishnan, S., & Singh, P. K. (2021) · Nanoscale · doi:10.1039/d1nr05385j · Cited by 22 · cited 9×
“[15,20,27,28,30,33,34,36,50,63].”
InfluentialMulgaonkar, A., Moeendarbari, S., Silvers, W., Hassan, G., Sun, X., Hao, Y., & Mao, W. (2017) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2017.2367 · Cited by 20 · cited 5×
“[15,20,27,28,30,33,34,36,50,63].”
InfluentialGhaffarlou, M., Mohammadi, A., Mousazadeh, N., Salehiabar, M., Kalantari, Y., Charmi, J., Barsbay, M., Ertas, Y. N., Danafar, H., Rezaeejam, H., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-40763-9 · Cited by 20 · cited 3×
“…was placed on functional modifications, including surface coatings, targeting ligands, biomimetic components, and therapeutic payloads, giving rise to multifunctional nanoplatforms capable of improving cellular uptake and integrating biological mechanisms of radiosensitization [24,27,29,55,66].”
Enhancing radiotherapy techniques for Triple-Negative breast cancer treatment
Sarlak, S., Pagès, G., & Luciano, F. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102939 · Cited by 19 · cited 4×
“…hypoxia, dysregulated DNA repair, oxidative stress adaptation, and an immunosuppressive tumor microenvironment, all of which contribute to radioresistance and provide a strong rationale for nanoparticle-assisted strategies designed to enhance radiation response and radiosensitization [2,5,7,93].”
InfluentialMusielak, M., Boś-Liedke, A., Piwocka, O., Kowalska, K., Markiewicz, R., Szymkowiak, B., Bakun, P., & Suchorska, W. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030862 · Cited by 18 · cited 2×
“From an experimental standpoint, most studies employed both in vitro and in vivo approaches [17,20,27,39,54], whereas a smaller subset relied exclusively on a single model type [30,57,58].”
Nicol, J. R., Harrison, E., O'Neill, S. M., Dixon, D., McCarthy, H. O., & Coulter, J. A. (2018) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2017.11.019 · Cited by 18 · cited 4×
“High-atomic-number (high-Z) nanomaterials were reported to increase local radiation energy deposition through photoelectric interactions, resulting in the generation of secondary electrons and localized dose amplification [15,20,27,28,34].”
InfluentialNanomaterials Based on Functional Polymers for Sensitizing Cancer Radiotherapy
Lin, J., Yin, M., Liu, X., Meng, F., & Luo, L. (2022) · Macromolecular Rapid Communications · doi:10.1002/marc.202200194 · Cited by 18 · cited 1×
“Surface modifications, including polyethylene glycol coatings, targeting ligands, and biomimetic carriers, were introduced to improve circulation time, tumor uptake, and cellular internalization [98–100].”
Wang, D., Lin, S., Li, T., Yang, X., Zhong, X., Chen, Q., Jiang, G., & Li, C. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101275 · Cited by 18 · cited 2×
“Immune-modulating strategies, including checkpoint-related approaches, were described in combination with radiotherapy in selected nanoplat-forms [17,21,23,26,39,56].”
Shi, J., Cui, G., Jin, Y., Mi, B., Liu, K., Zhao, L., Bao, K., Lu, Z., Liu, J., Wang, Y., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202402474 · Cited by 18 · cited 1×
“Ferroptosis was reported in several studies, particularly in association with redox modulation and glutathione depletion [15,17,68,77,78], while additional pathways such as pyroptosis were also described [16,39].”
Zhu, Z., Wu, M., Sun, J., Huangfu, Z., Yin, L., Yong, W., Sun, J., Wang, G., Meng, F., & Zhong, Z. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1995080 · Cited by 17 · cited 1×
“Therapeutic payload delivery was also commonly described, including chemotherapeutic agents, epigenetic modulators, and nucleic acid-based therapeutics [27,42,45,52,71–73].”
Zhang, L., Zheng, B., Guo, R., Miao, Y., & Li, B. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb00186h · Cited by 17 · cited 1×
“X-ray X-ray irradiation was the most frequently reported modality [17,20,27,34,54], whereas megavoltage radiation and radionuclide-based approaches were less commonly used [20,24,61,62].”
Mostafavi, M., Ghazi, F., Mehrabifard, M., Alivirdiloo, V., Hajiabbasi, M., Rahimi, F., Mobed, A., Taheripak, G., Ramezani Farani, M., Huh, Y. S., et al. (2025) · Strahlentherapie und Onkologie · doi:10.1007/s00066-024-02301-y · Cited by 16 · cited 6×
“High-Z nanomaterials amplify these effects by increasing local energy deposition and secondary electron generation, thereby enhancing intracellular ROS production and DNA damage [10,85,86,88].”
InfluentialChoi, E., Jeon, K., Lee, H., Mun, G., Kim, J., Shin, J., Kwon, Y., Na, Y., & Lee, Y. (2024) · Cancer Science · doi:10.1111/cas.16174 · Cited by 15 · cited 4×
“…hypoxia, dysregulated DNA repair, oxidative stress adaptation, and an immunosuppressive tumor microenvironment, all of which contribute to radioresistance and provide a strong rationale for nanoparticle-assisted strategies designed to enhance radiation response and radiosensitization [2,5,7,93].”
InfluentialShao, L., Liu, D., Liu, X., Wang, X., Yang, X., Niu, R., Yin, S., Xu, P., Mao, Y., Du, X., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117402 · Cited by 14 · cited 10×
“Such systems frequently incorporated catalytic and microenvironment-responsive components designed to address tumor hypoxia, redox imbalance, and metabolic vulnerabilities within the tumor microenvironment [17,19,21,43,47,53].”
InfluentialMing, Z., Zhang, Y., Song, L., Chen, M., Lin, L., He, Y., Liu, W., Zhu, Y., Zhang, Y., & Zhang, G. (2024) · Advanced Science · doi:10.1002/advs.202309992 · Cited by 13 · cited 10×
“Many nanoplatforms incorporated targeting ligands, therapeutic payloads, and microenvironment-responsive components [16,17,26,27,45,49,51–53].”
InfluentialSilver sulfide coated alginate radioenhancer for enhanced X-ray radiation therapy of breast cancer
Mousazadeh, N., Seidi, F., Ghaffarlou, M., Rashidzadeh, H., Hosseinmirzaei, A., Mozafari, F., Danafar, H., & Nosrati, H. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123636 · Cited by 13 · cited 1×
“Therapeutic payload delivery was also commonly described, including chemotherapeutic agents, epigenetic modulators, and nucleic acid-based therapeutics [27,42,45,52,71–73].”
Sun, W. Y., Lee, D.-S., Park, J. H., Kim, O.-H., Choi, H. J., & Kim, S.-J. (2025) · Journal of Breast Cancer · doi:10.4048/jbc.2024.0262 · Cited by 12
Zetrini, A. E., Abbasi, A. Z., He, C., Lip, H., Alradwan, I., Rauth, A. M., Henderson, J. T., & Wu, X. Y. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101206 · Cited by 12 · cited 10×
“Beyond this effect, several nanoplatforms were specifically designed to inhibit DNA repair pathways, thereby prolonging damage persistence and increasing radiosensitivity [15,52,74].”
InfluentialMageau, E., Derbowka, R., Dickinson, N., Lefort, N., Kovala, A. T., Boreham, D. R., Tai, T. C., Thome, C., & Tharmalingam, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47080589 · Cited by 12 · cited 7×
“Radioresistance in breast cancer is a multifactorial process involving tumor cell-intrinsic mechanisms, including enhanced DNA damage repair capacity, dysregulated cell cycle checkpoints, and resistance to apoptosis, as well as extrinsic factors related to the tumor microenvironment [4].”
InfluentialBiagiotti, G., Cazzoli, R., Andreozzi, P., Aresta, G., Francesco, M., Mangini, C., di Gianvincenzo, P., Tobia, C., Recchia, S., Polito, L., et al. (2024) · Nanoscale Horizons · doi:10.1039/d4nh00042k · Cited by 11
Chen, S.-F., Ng, P.-L., Lai, C.-W., Wang, F.-J., Wang, Y.-C., Chen, M.-H., Tung, F.-I., & Liu, T.-Y. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03187-3 · Cited by 11 · cited 5×
“Inhibition of metastatic progression and systemic tumor control were also reported in selected studies [22,43,45].”
InfluentialRahmani, A., Maleki, A., Jafari, R., Rezaeejam, H., & Nadri, S. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00789e · Cited by 10
Tarantino, S., Bianco, A., Cascione, M., Carlà, A., Fiamà, L., Di Corato, R., Giotta, L., Pellegrino, P., Caricato, A. P., Rinaldi, R., et al. (2025) · Discover Nano · doi:10.1186/s11671-025-04186-x · Cited by 10 · cited 2×
“High-Z nanoparticles enhance ROS generation by increasing local energy deposition and secondary electron emission, thereby amplifying free radical formation and oxidative stress following irradiation [9,10,86,88,102,103].”
Bienassis, C., Vivar, O. I., Hu, Y., Da silva, J., Darmon, A., Marill, J., Anesary, N. M., Schmitt, P., Levy, L., Welsh, J., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03579-1 · Cited by 9
Peng, J., Quan, D.-L., Yang, G., Wei, L.-T., Yang, Z., Dong, Z.-Y., Zou, Y.-M., Hou, Y.-K., Chen, J.-X., Lv, L., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-03013-2 · Cited by 9
Liu, J., Zhao, L., Sun, Y., Fu, Q., & Xiao, W. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102186 · Cited by 9 · cited 2×
“…long-term toxicity, immunogenicity, manufacturing scalability, and regulatory reproducibility were infrequently evaluated [10,11,13,16,93–100 , 102 Taken together, these limitations highlight the need for greater methodological standardization in preclinical nanoparticle-assisted…”
Yang, Z., Shao, B., Wang, D., Chen, H., Zhao, X., Zeng, M., Liu, Y., Li, Q., & Bi, Z. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2025.123787 · Cited by 8 · cited 9×
“Many nanoplatforms incorporated targeting ligands, therapeutic payloads, and microenvironment-responsive components [16,17,26,27,45,49,51–53].”
InfluentialShin, S., Bae, G.-H., Park, J. D., Koh, E.-Y., Ko, S., Han, J., Park, C. G., Kim, D.-H., Na, K., & Park, W. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124002 · Cited by 8 · cited 10×
“Additional strategies included depletion of intracellular glutathione (GSH) and modulation of redox balance [17,19,45,47,68], as well as metabolic interventions targeting glycolysis or cellular energetics [49,69,75,76].”
InfluentialThabet, N. M., Abdel-Rafei, M. K., El-Sayyad, G. S., Elkodous, M. A., Shaaban, A., Du, Y.-C., Rashed, L. A., & Askar, M. A. (2022) · Cancer Nanotechnology · doi:10.1186/s12645-022-00122-1 · Cited by 7
Chen, S., Wang, C., Meng, Y., Li, P., Pan, Y., He, M., & Ni, X. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s441418 · Cited by 7 · cited 2×
“Biomimetic strategies, including cell membrane-coated nanoparticles, were reported to enhance circulation time and immune evasion [34,44,50,56].”
Aghaei, A., Shaterian, M., Danafar, H., Likozar, B., Šuligoj, A., & Gyergyek, S. (2023) · Microchimica Acta · doi:10.1007/s00604-023-05761-8 · Cited by 7 · cited 1×
“…frequently associated with enhanced therapeutic activity compared with radiotherapy alone, including reduced cell viability, decreased clonogenic survival, increased apoptosis, enhanced DNA damage, delayed tumor growth, and, in selected studies, improved survival outcomes [14,23,26,87,96,104,105].”
Zhang, J., Lu, L., Zhang, W., Miao, Y., Du, H., Xia, H., Tao, Z., Du, Z., Tang, Y., & Fang, Q. (2025) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2024.114374 · Cited by 7 · cited 4×
“In RDT systems, X-ray irradiation activates radiosensitizing or photosensitizer-like components incorporated within nanoplatforms, resulting in active ROS generation through radiation-triggered photochemical processes [39–41 , 68 ].”
InfluentialZeng, B., Ling, K., Yuan, Q., Chen, Z., Zhang, G., Kang, W., Zheng, X., Liao, C., Mai, Y., Huang, Z., et al. (2026) · Theranostics · doi:10.7150/thno.124034 · Cited by 7 · cited 10×
“…hypoxia while enhancing ROS production [17,19,21], drug-loaded systems that combine radiotherapy with chemotherapy or DNA repair inhibition [23,45,52], and immune-active nanoplatforms capable of promoting dendritic cell maturation, cGAS–STING activation, and CD8 + T-cell infiltration…”
InfluentialLi, M., Lin, L., Guo, T., Wu, Y., Lin, J., Liu, Y., Yang, K., & Hu, C. (2021) · BioMed Research International · doi:10.1155/2021/9262453 · Cited by 7
Anceschi, C., Scavone, F., Armanetti, P., Menichetti, L., Catarinicchia, C., Borri, C., Ratto, F., Micheletti, F., Formica, N., Ruzzolini, J., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202502416 · Cited by 7 · cited 4×
“Although these combinatorial systems often demonstrate enhanced efficacy experimentally, their clinical development is challenged by issues related to reproducibility, manufacturing consistency, regulatory approval, scalability, and long-term safety [25,96,97].”
InfluentialEvaluation of efficacy of tumor-specific nanoliposomal radiosensitizer in radiotherapy
Karabuga, M., Erdogan, S., Filikci, K., Hazıroglu, R., Tuncel, M., & Cengiz, M. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104586 · Cited by 6 · cited 1×
“Safety assessments were reported in a proportion of studies, with limited systemic toxicity observed based on body weight, organ histology, and hematological parameters [34,40,48,83].”
Wang, Y., Han, X., Zhang, S., Wang, L., Sun, S., Xue, C., & Yao, T. (2025) · Biopolymers · doi:10.1002/bip.70054 · Cited by 6 · cited 9×
“Hybrid systems were therefore developed to combine the favorable physical properties of high-Z materials with additional functionalities capable of modulating the tumor microenvironment, enhancing tumor targeting, or amplifying oxidative stress through catalytic mechanisms [17,19,21,39,40].”
InfluentialLi, P., Dong, Z., Jiang, Q., Yu, C., Liu, Y., Yuan, R., Qiu, Y., Meng, T., Hu, F., & Yuan, H. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114406 · Cited by 6 · cited 2×
“Additional strategies included depletion of intracellular glutathione (GSH) and modulation of redox balance [17,19,45,47,68], as well as metabolic interventions targeting glycolysis or cellular energetics [49,69,75,76].”
Montazersaheb, S., Farahzadi, R., Mansouri, E., Jafari, S., & Fathi, E. (2026) · Scientific Reports · doi:10.1038/s41598-026-35662-8 · Cited by 5 · cited 10×
“Subsequently, catalytic and microenvironment-responsive systems emerged to modulate tumor hypoxia, redox balance, and oxidative stress dy-https namics, thereby extending radiosensitization beyond simple physical dose amplification [17,19,21,31,53].”
InfluentialAtkinson, J., Chopin, J., Bezak, E., Le, H., & Kempson, I. (2025) · ChemPhysChem · doi:10.1002/cphc.202400764 · Cited by 5
Salarvand, A., Shanei, A., Hejazi, S. H., Abedi, I., & Kakhki, N. A. (2025) · Advanced Biomedical Research · doi:10.4103/abr.abr_221_24 · Cited by 5 · cited 10×
“These platforms typically incorporate catalytic components, including manganese, iron, or copper-containing materials, that exploit endogenous hydrogen peroxide within the tumor microenvironment to generate highly reactive hydroxyl radicals through Fenton or Fenton-like reactions [87,90].”
InfluentialDastgir, M., Ayyami, Y., Ghorbani, M., Yektamanesh, M., Ghasemi Jangjoo, A., Zamani, H., Jazzi, S. S., Mehrizi, O. A., Mortezazadeh, T., & Malekzadeh, R. (2026) · Cancer Nanotechnology · doi:10.1186/s12645-025-00359-6 · Cited by 4
siRNA Nanoparticle Delivery Strategies and Clinical Trial Advances in Tumor Therapy
Wang, P., Gong, J., Xu, Y., & Xia, X. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073032 · Cited by 4 · cited 1×
“…siRNA delivery, these findings suggest that biologically inspired delivery systems may further enhance the therapeutic potential of nucleic acid-based radiosensitization strategies by improving intracellular delivery, protecting RNA cargo from degradation, and reducing off-target effects [109–111].”
Hussein, M. A., Hamdy, A. M., Abdelrhman, I. G., et al. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096364549250828062651 · Cited by 4 · cited 1×
“HER2-positive and luminal subtypes were less frequently investigated [29,51,57,59,60], and a limited number of studies included multiple subtypes within the same experimental design [28,57].”
Shiridokht, F., Kehtari, P., Eskandani, M., Farajollahi, A., & Vandghanooni, S. (2025) · International Journal of Pharmaceutics: X · doi:10.1016/j.ijpx.2025.100419 · Cited by 4 · cited 3×
“Although these combinatorial systems often demonstrate enhanced efficacy experimentally, their clinical development is challenged by issues related to reproducibility, manufacturing consistency, regulatory approval, scalability, and long-term safety [25,96,97].”
Kan, X., Wang, J., Li, Y., Li, D., Li, F., Huang, C., & Liu, P. (2026) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2025.115397 · Cited by 3 · cited 1×
“Receptor-specific targeting, including HER2, CXCR4, and folate-directed systems, was frequently described and associated with increased cellular uptake [20,24,29,49,51,55,70].”
Zhang, H., Liu, Y., Gao, X., Ji, G., Zheng, Y., Luo, F., Qi, X., Zhao, S., Guan, S., Wang, C., et al. (2025) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2025.102870 · Cited by 3 · cited 4×
“While these systems often demonstrated strong preclinical efficacy [17,21,23,39,40,45,52,68,76,77], their translational feasibility remains uncertain because biodistribution, pharmacokinetics, long-term toxicity, immunogenicity, manufacturing scalability, and regulatory reproducibility were…”
InfluentialUti, D. E., Egbung, J. E., Anthony, B. O., Omari, O. R., Omang, W. A., Aggad, W. S., Almohaimeed, H. M., Bainsal, N., Shukla, S. K., Ealla, K. K. R., et al. (2026) · Discover Nano · doi:10.1186/s11671-026-04681-9 · Cited by 3 · cited 1×
“In particular, exosome-based and exosome-mimicking systems have attracted increasing interest because of their intrinsic biocompatibility, tumor-homing potential, and ability to facilitate intracellular transport of functional cargo [106–108].”
Albers, J., Markus, A., Svetlove, A., Kraupner, A., Briel, A., Alves, F., & Dullin, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-02560-4 · Cited by 3 · cited 1×
“From an experimental standpoint, most studies employed both in vitro and in vivo approaches [17,20,27,39,54], whereas a smaller subset relied exclusively on a single model type [30,57,58].”
Novel Pt@BSA nanoparticles improve radiotherapeutic outcomes in breast cancer
Zhang, Y., Liu, Y., & Zheng, D. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md00792e · Cited by 3
Radiosensitizers in Cancer Therapy: A Global Bibliometric Analysis
Annagiri, S., Harary, P. M., Hori, Y. S., Lam, F. C., AbuReesh, D., Tayag, A., Ustrzynski, L., Emrich, S. C., Chang, S. D., & Park, D. J. (2025) · doi:10.1101/2025.06.26.661878 · Cited by 3 · cited 7×
“…local radiation absorption, secondary electron generation, and ROS production, they do not directly address major biological determinants of radioresistance, including tumor hypoxia, antioxidant defenses, DNA repair capacity, immune suppression, and heterogeneous nanoparticle delivery [4,12,85,93].”
Influential
Metadata
- Authors
- Lunca, S., Morarasu, S., & Dimofte, G. M.
- Affiliations
- Grigore T Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
- Grigore T. Popa University of Medicine and Pharmacy (RO)
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2026-07-22
- Volume
- 27
- Issue
- 14
- Pages
- 6522
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC13411440
- OpenAlex
- W7170042542
- Cited by
- 2
- References
- 114
- Citations by year
- 2026: 2
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- Grigore T. Popa University of Medicine and Pharmacy (326475)
- Topics
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Physics and Astronomy › Radiation › Advanced Radiotherapy Techniques
- Keywords
- breast cancer, radioresistance (biology), gold nanoparticles, platinum nanoparticles, bismuth nanoparticles, gadolinium nanoparticles, reactive oxygen species, redox modulation, tumor microenvironment, triple-negative breast cancer, immune activation, translational challenges
- MeSH terms
- Animals, Breast Neoplasms, Female, Humans, Radiation Tolerance, Radiation-Sensitizing Agents, Nanoparticles, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.